RxSight (RXST) to Release Quarterly Earnings on Monday

RxSight (NASDAQ:RXST - Get Free Report) is scheduled to release its earnings data after the market closes on Monday, May 6th. Analysts expect RxSight to post earnings of ($0.17) per share for the quarter. RxSight has set its FY 2024 guidance at EPS.Persons interested in participating in the company's earnings conference call can do so using this link.

RxSight (NASDAQ:RXST - Get Free Report) last released its earnings results on Wednesday, February 28th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.10. RxSight had a negative return on equity of 31.16% and a negative net margin of 54.57%. The company had revenue of $28.58 million during the quarter, compared to analysts' expectations of $28.60 million. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

RxSight Stock Up 0.9 %

Shares of RxSight stock traded up $0.49 during trading on Monday, reaching $53.26. 423,365 shares of the company were exchanged, compared to its average volume of 427,085. RxSight has a twelve month low of $17.59 and a twelve month high of $58.21. The business has a 50-day moving average price of $52.55 and a 200-day moving average price of $42.14. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of -37.24 and a beta of 1.22.

Analyst Ratings Changes

RXST has been the subject of a number of analyst reports. Oppenheimer lifted their price objective on RxSight from $54.00 to $61.00 and gave the stock an "outperform" rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. boosted their target price on RxSight from $40.00 to $62.00 and gave the company an "overweight" rating in a research note on Thursday, February 29th. Needham & Company LLC reissued a "buy" rating and issued a $64.00 target price on shares of RxSight in a research note on Thursday, April 11th. Finally, Stifel Nicolaus boosted their target price on RxSight from $54.00 to $64.00 and gave the company a "buy" rating in a research note on Thursday, February 29th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $49.63.

Insider Activity

In other news, Director Bakker Juliet Tammenoms purchased 4,000 shares of the business's stock in a transaction dated Monday, February 12th. The shares were bought at an average cost of $50.38 per share, for a total transaction of $201,520.00. Following the completion of the acquisition, the director now directly owns 25,840 shares in the company, valued at approximately $1,301,819.20. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO Shelley B. Thunen sold 20,000 shares of the company's stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $49.90, for a total transaction of $998,000.00. Following the sale, the chief financial officer now owns 8,402 shares in the company, valued at $419,259.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bakker Juliet Tammenoms bought 4,000 shares of the company's stock in a transaction that occurred on Monday, February 12th. The shares were bought at an average price of $50.38 per share, for a total transaction of $201,520.00. Following the acquisition, the director now directly owns 25,840 shares of the company's stock, valued at approximately $1,301,819.20. The disclosure for this purchase can be found here. Insiders have sold a total of 94,869 shares of company stock worth $4,771,244 over the last three months. Corporate insiders own 21.13% of the company's stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.